110 assets in Gastroesophageal Junction Adenocarcinoma

Therapeutic assets addressing Gastroesophageal Junction Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P3	BBB (74)
Cyclophosphamide Gastroesophageal Junction Adenocarcinoma	Beijing Biotech	P3	BB (71)
Fluorouracilum Gastroesophageal Junction Adenocarcinoma	Alliance for Clinical Trials in Oncology	P3	BB (70)
Pembrolizumab Gastroesophageal Junction Adenocarcinoma	Eikon Therapeutics	P3	BB (70)
Capecitabine Gastroesophageal Junction Adenocarcinoma	I-Mab Biopharma US Limited	P3	BB (69)
Levofolinic Acid Gastroesophageal Junction Adenocarcinoma	Merck Sharp & Dohme LLC	P3	BB (68)
Oxaliplatin Gastroesophageal Junction Adenocarcinoma	Alliance for Clinical Trials in Oncology	P3	BB (68)
Disitamab Vedotin Gastroesophageal Junction Adenocarcinoma	BeOne Medicines	P2	BB (67)
Cis-Diamminedichloroplatinum Ii Gastroesophageal Junction Adenocarcinoma	Shenyang Sunshine Pharmaceutical Co., LTD.	P3	BB (66)
Docetaxel Gastroesophageal Junction Adenocarcinoma	Kyowa Kirin Co., Ltd.	P3	BB (66)
Trastuzumab Gastroesophageal Junction Adenocarcinoma	Boehringer Ingelheim	P3	BB (65)
Nivolumab Gastroesophageal Junction Adenocarcinoma	I-Mab Biopharma US Limited	P2	B (61)
Givastomig Gastroesophageal Junction Adenocarcinoma	I-Mab Biopharma US Limited	P2	B (60)
Rivoceranib Gastroesophageal Junction Adenocarcinoma	Yunpeng Liu	P2	B (60)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer Gastroesophageal Junction Adenocarcinoma	Merck Sharp & Dohme LLC	P1/2	B (58)
Tislelizumab Gastroesophageal Junction Adenocarcinoma	BeOne Medicines	P1/2	B (57)
Avapritinib Gastroesophageal Junction Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
azd0901 Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P2	CCC (53)
Hydroxychloroquine Gastroesophageal Junction Adenocarcinoma	Northwestern University	P2	CCC (53)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Gastroesophageal Junction Adenocarcinoma	Yunpeng Liu	P2	CCC (53)
Ssgj-706 Gastroesophageal Junction Adenocarcinoma	Shenyang Sunshine Pharmaceutical Co., LTD.	P2	CCC (53)
Tucatinib Gastroesophageal Junction Adenocarcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
e-602 Gastroesophageal Junction Adenocarcinoma	Palleon Pharmaceuticals, Inc.	P1/2	CCC (52)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Gastroesophageal Junction Adenocarcinoma	Palleon Pharmaceuticals, Inc.	P1/2	CCC (52)
Trastuzumab Deruxtecan Gastroesophageal Junction Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CCC (52)
Vebreltinib Gastroesophageal Junction Adenocarcinoma	Apollomics Inc.	P2	CCC (51)
Futibatinib Gastroesophageal Junction Adenocarcinoma	Taiho Oncology, Inc.	P2	CCC (50)
ab-201 Gastroesophageal Junction Adenocarcinoma	GC Cell Corporation	P1/2	CCC (48)
azd4360 Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P1/2	CCC (48)
azd5863 Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P1/2	CCC (48)
bhb810 Gastroesophageal Junction Adenocarcinoma	BigHat Biosciences, Inc.	P1/2	CCC (48)
bi-1607 Gastroesophageal Junction Adenocarcinoma	BioInvent International AB	P1/2	CCC (48)
Bms-936558-01 Gastroesophageal Junction Adenocarcinoma	Bristol-Myers Squibb	P1/2	CCC (48)
Carboplatin Gastroesophageal Junction Adenocarcinoma	Neonc Technologies, Inc.	P1/2	CCC (48)
eik1005 Gastroesophageal Junction Adenocarcinoma	Eikon Therapeutics	P1/2	CCC (48)
Fludarabine Gastroesophageal Junction Adenocarcinoma	Beijing Biotech	P1/2	CCC (48)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Cc Chemokine Receptor Ccr8) (Human-Mus Musculus Monoclonal Bms-986340 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Bms-986340 ?-Chain, Dimer Gastroesophageal Junction Adenocarcinoma	Bristol-Myers Squibb	P1/2	CCC (48)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody; Conjugated To Auristatin E Gastroesophageal Junction Adenocarcinoma	Shanghai Miracogen Inc.	P1/2	CCC (48)
Mdna11 Gastroesophageal Junction Adenocarcinoma	Medicenna Therapeutics, Inc.	P1/2	CCC (48)
Pumitamig Gastroesophageal Junction Adenocarcinoma	Bristol-Myers Squibb	P1/2	CCC (48)
Sargramostim Gastroesophageal Junction Adenocarcinoma	Mayo Clinic	P1/2	CCC (48)
azd7789 Gastroesophageal Junction Adenocarcinoma	AstraZeneca	P1/2	CC (47)
Devimistat Gastroesophageal Junction Adenocarcinoma	Northwestern University	P2	CC (47)
Dual-Target Car-Nk Cells Gastroesophageal Junction Adenocarcinoma	Beijing Biotech	P1/2	CC (47)
her3-dxd Gastroesophageal Junction Adenocarcinoma	Merck Sharp & Dohme LLC	P1/2	CC (47)
Osemitamab Gastroesophageal Junction Adenocarcinoma	Suzhou Transcenta Therapeutics Co., Ltd.	P1/2	CC (47)
Patritumab Deruxtecan Gastroesophageal Junction Adenocarcinoma	Merck Sharp & Dohme LLC	P1/2	CC (47)
Petosemtamab Gastroesophageal Junction Adenocarcinoma	Merus B.V.	P1/2	CC (47)
Sacituzumab Tirumotecan Gastroesophageal Junction Adenocarcinoma	Merck Sharp & Dohme LLC	P1/2	CC (47)
Sonidegib Gastroesophageal Junction Adenocarcinoma	Mayo Clinic	P1	CC (47)

Showing 1 to 50 of 110 assets

PreviousPage 1 of 3Next